# US 2016/0256511 A1 · Compositions and methods for the treatment or prophylaxis of circadian protein related conditions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0256511 A1
- Document ID: US20160256511A1
- Status: Published application
- Kind: A1
- Application number: 14/431,097
- Filed: 2014-11-13
- Published: 2016-09-08
- Earliest claimed: 2013-11-13
- Assignees: IN Ingredients, Inc.
- Applicants: In Ingredients, Inc.
- Inventors: Bolin Qin; Augustin T. Romero; Tim Romero
- Web page: https://patentgrep.com/patent/US20160256511A1

## CPC

- A61K 36/53: Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A23K 20/10: Organic substances
- A23K 20/105: Aliphatic or alicyclic compounds
- A23K 20/158: Fatty acids; Fats; Products containing oils or fats
- A23L 33/105: Plant extracts, their artificial duplicates or their derivatives
- A61K 31/19: Carboxylic acids, e.g. valproic acid (salicylic acid A61K31/60)
- A61K 31/56: Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K 36/88: Liliopsida (monocotyledons)
- A61K 36/896: Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/06: Antihyperlipidemics
- A61P 3/08: for glucose homeostasis (pancreatic hormones A61P5/48)
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 5/00: Drugs for disorders of the endocrine system
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/06: Antiarrhythmics
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/12: Antihypertensives
- A61P 13/08: of the prostate
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/20: Hypnotics; Sedatives
- A61P 25/24: Antidepressants
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A23V 2002/00: Food compositions, function of food ingredients or processes for food or foodstuffs
- A61K 2236/331: using water, e.g. cold water, infusion, tea, steam distillation or decoction
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A23K: FODDER
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A23V: INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION

## Abstract

Provided are compositions and processes of treating or preventing one or more conditions related to a protein involved in circadian rhythm. A composition includes an extract of rosemary, an extract of hemerocallis fulva, active portion or component thereof, or combinations thereof, optionally provided as a component of a dietary supplement. The presence of one or more active ingredients in the extracts optionally administered at a targeted administration time alters the expression of one or more genes or proteins involved in circadian rhythm, illustratively CLOCK, BMAL1, FBXL3, FBXL21, or SIRT1.

## Claims

### Claim 1

A composition for the treatment or prevention of a disease or condition related to the expression of a circadian rhythm related protein comprising:
an effective amount of an extract of rosemary, an extract of hemerocallis fulva, active portion or component thereof, or combinations thereof, said extract formulated for administering to a subject in need of treatment of a disease or condition related to a circadian rhythm; and
ameliorating, preventing, or modulating a symptom of said disease or condition in said subject whereby said effective amount is sufficient to alter one or more expression characteristics of a protein selected from the group consisting of CLOCK, BMAL1, FBXL3, FBXL21, SIRT1, or combinations thereof, in said subject.

### Claim 2 (depends on 1)

The composition of claim 1 wherein said extract is a water extract.

### Claim 3 (depends on 1)

The composition of claim 1 wherein extract is a component in a dietary supplement.

### Claim 4 (depends on 1)

The composition of claim 1 wherein said administering is once daily.

### Claim 5 (depends on 1)

The composition of claim 1 wherein said extract is an extract of rosemary and said protein is the BMAL1 protein.

### Claim 6 (depends on 1)

The composition of claim 1 wherein said extract is an extract of rosemary and said protein is FBXL3, FBXL21, or combinations thereof.

### Claim 7 (depends on 1)

The composition of claim 1 wherein said extract is an extract of rosemary and said protein is SIRT1.

### Claim 8 (depends on 1)

The composition of claim 1 wherein said extract is an extract of hemerocallis fulva and said protein is CLOCK.

### Claim 9 (depends on 1)

The composition of claim 1 wherein said extract is an extract of hemerocallis fulva and said protein is BMAL1.

### Claim 10 (depends on 1)

The composition of claim 1 wherein said extract is an extract of hemerocallis fulva and said protein is FBXL3, FBXL21, or combinations thereof.

### Claim 11 (depends on 1)

The composition of claim 1 wherein said extract is an extract of hemerocallis fulva and said protein is SIRT1.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The composition of any one of claims 1-11 wherein said disease or condition is jet lag.

### Claim 13 (depends on 12)

The composition of claim 12 wherein said administration is prior to or following travel involving a change in time zone.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The composition of any one of claims 1-11 wherein said disease or condition is a hangover.

### Claim 15 (depends on 14)

The composition of claim 14 wherein said extract is administered prior to, during, or following the consumption of alcohol, or combinations thereof.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The composition of any one of claims 1-11 wherein said disease or condition is a metabolic condition related to an expression characteristic of one or more of CLOCK, BMAL1, FBXL3, FBXL21, or SIRT1.

### Claim 18 (depends on 16)

The composition of claim 16 wherein said metabolic conditions is abnormal cholesterol level, obesity, metabolic syndrome or element thereof, hyperglycemia, hypoglycemia, abnormal insulin production, or diabetes.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The composition of any one of claims 1-11 wherein said disease or condition is an inflammatory disorder related to an expression characteristic of one or more of CLOCK, BMAL1, FBXL3, FBXL21, of SIRT1.

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The composition of any one of claims 1-11 wherein said disease or condition is a neurological disorder related to an expression characteristic of one or more of CLOCK, BMAL1, FBXL3, FBXL21, of SIRT1.

### Claim 21 (depends on 20)

The composition of claim 20 wherein said neurological disorder is Alzheimer's disease.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The composition of any one of claims 1-11 wherein said disease or condition is a muscular disorder related to an expression characteristic of one or more of CLOCK, BMAL1, FBXL3, FBXL21, of SIRT1.

### Claim 23 (depends on 22)

The composition of claim 22 wherein said muscular disorder is muscular dystrophy or myopathy.

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The composition of any one of claims 1-11 wherein said disease or condition is a sleep disorder related to an expression characteristic of one or more of CLOCK, BMAL1, FBXL3, FBXL21, of SIRT1.

### Claim 25 (depends on 24)

The composition of claim 24 wherein said sleep disorder is insomnia, jet lag, shift work sleep disorder, delayed sleep phase syndrome (DSPS), advanced sleep phase syndrome (ASPS), non 24-hour sleep wake disorder or irregular sleep-wake pattern.

### Claim 26 (depends on 25)

The composition of claim 25 wherein said administration is from −4 hours to 12 hours or 0 to 12 hours after light exposure.

### Claim 27 (depends on 25)

The composition of claim 25 wherein said administration is from 1-3 hours after light exposure or 10-14 hours after light exposure.

### Claim 28 (depends on 25)

The composition of claim 25 wherein said administration is from 4 hours to 0 hours prior to light exposure.

### Claim 29 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The composition of any one of claims 1-11 wherein said disease or condition is a psychiatric disorder related to an expression characteristic of one or more of CLOCK, BMAL1, FBXL3, FBXL21, of SIRT1.

### Claim 30 (depends on 29)

The composition of claim 29 wherein said psychiatric disorder is depression, seasonal affective disorder, dementia, or rapid-cycling bipolar disorder.

### Claim 31 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The composition of any one of claims 1-11 wherein said disease or condition is a cardiovascular disorder related to an expression characteristic of one or more of CLOCK, BMAL1, FBXL3, FBXL21, of SIRT1.

### Claim 32 (depends on 31)

The composition of claim 31 wherein said cardiovascular disorder is abnormal blood pressure or abnormal heart rate.

### Claim 33 (depends on 31)

The composition of claim 31 wherein said cardiovascular disorder is atherosclerosis or cardiomyopathy.

### Claim 34 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The composition of any one of claims 1-11 wherein said disease or condition is a liver toxicity related to an expression characteristic of one or more of CLOCK, BMAL1, FBXL3, FBXL21, of SIRT1.

### Claim 35 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The composition of any one of claims 1-11 wherein said disease or condition is a disorder of the brain related to an expression characteristic of one or more of CLOCK, BMAL1, FBXL3, FBXL21, of SIRT1.

### Claim 36 (depends on 35)

The composition of claim 35 wherein said disorder of the brain is stroke or brain degeneration due to free radicals.

### Claim 37 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The composition of any one of claims 1-11 wherein said composition is administered on an as needed basis.

### Claim 38 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The composition of any one of claims 1-11 wherein said protein is not SIRT1.

### Claim 39 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The composition of any one of claims 1-11 wherein said extract comprises ursolic acid at 10% by weight or greater.

### Claim 40 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The composition of any one of claims 1-11 wherein said extract comprises ursolic acid at 25% by weight or greater.

### Claim 41 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The composition of any one of claims 1-11 wherein said extract consists of ursolic acid.

### Claim 42 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The composition of any one of claims 1-11 wherein said administration is for a period of 2 weeks or more.

### Claim 43 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The composition of any one of claims 1-11 wherein said administration is for four weeks or more.

### Claim 44 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The composition of any one of claims 1-11 wherein said administration is for three months or more.

### Claim 45 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The composition of any one of claims 1-11 wherein said administration is once, twice, three, or four times daily.

### Claim 46 (depends on 3)

The composition of claim 3 wherein said dietary supplement is in the form of a powder, gel, liquid, food, solid, or other form.

### Claim 47

A composition for treating or preventing obesity in a subject in need thereof comprising:
an extract of rosemary, an extract of hemerocallis fulva, active portion or component thereof, or combinations thereof, said extract for administration to a subject in need of treatment or prevention of obesity;
said obesity related to an expression characteristic or CLOCK, BMAL1, FBXL3, FBXL21, SIRT1, or combinations thereof;
and ameliorating, preventing, or modulating obesity in said subject whereby said effective amount is sufficient to alter one or more expression characteristics of a protein selected from the group consisting of CLOCK, BMAL1, FBXL3, FBXL21, SIRT1, or combinations thereof, in said subject.

### Claim 48

A composition for treating or preventing cancer in a subject in need thereof comprising:
an extract of rosemary, an extract of hemerocallis fulva, active portion or component thereof, or combinations thereof, said extract for administration to a subject in need of treatment or prevention of cancer;
said cancer related to an expression characteristic or CLOCK, BMAL1, FBXL3, FBXL21, SIRT1, or combinations thereof;
and ameliorating, preventing, or modulating cancer in said subject whereby said effective amount is sufficient to alter one or more expression characteristics of a protein selected from the group consisting of CLOCK, BMAL1, FBXL3, FBXL21, SIRT1, or combinations thereof, in said subject.

### Claim 49

A process substantially as described in the specification.

### Claim 50

A composition substantially as described in the specification.
